A Study to Evaluate the Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis

NCT05424887 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

105

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

DRUG: AK3280
DRUG: Placebo

Sponsor

Shanghai Ark Biopharmaceutical Co., Ltd.